MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company dedicated to advancing therapies for immunologic and inflammatory conditions. Its primary focus is the clinical development of sonelokimab, a proprietary tri-specific Nanobody that selectively binds to interleukin-17A (IL-17A), interleukin-17F (IL-17F), and human serum albumin. The company is advancing this asset through multiple Phase 2 and Phase 3 clinical trials for indications including hidradenitis suppurativa (HS) and active psoriatic arthritis (PsA). By utilizing Nanobody technology, which features a smaller molecular size than traditional antibodies, MoonLake aims to achieve deeper tissue penetration in affected joints and skin. The company operates globally from its headquarters in Switzerland, managing clinical trials and regulatory pathways across major pharmaceutical markets.
